ITMCTR2023000056RecruitingPhase 1
Evaluation of the efficacy of Ruanjian Qingmai granules in the treatment of peripheral arterial disease after revascularization
Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine0 sitesStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40 to 90 (—)
- Sex
- All
Inclusion Criteria
- •(1) Clinical data before undergoing revascularization meet the diagnostic criteria of PAD in the Guidelines for Diagnosis and Treatment of Lower Extremity Atherosclerotic Occlusive Disease 2016 compiled by the Vascular Surgery Group of the Surgery Branch of the Chinese Medical Association, as well as meet the diagnostic criteria of desmoplasia in the Diagnostic Efficacy Criteria for Chinese Medicine Internal Medicine Disease (ZY/T001.1-94) of the Chinese People's Republic of China Traditional Chinese Medicine Industry Standard; (2) 40 < age = 90 years old, gender is not limited; (3) have undergone lower limb revascularization within the last 6 months; (4) agree to participate in this clinical trial and voluntarily sign the informed consent.
Exclusion Criteria
- •(1) patients with acute lower extremity ischemia scheduled for lower extremity revascularization and those with a history of major amputation; (2) patients with occlusion of the common femoral or above, femoro-iliac arteries, or occlusion of the arteries above the groin; (3) patients with inflammatory vascular diseases such as atherosclerotic occlusions of the non-lower extremity arteries such as multiple large arteritis, thrombo-occlusive vasculitis, and others; (4) patients who have had a pulmonary embolism in the last 3 months, a myocardial infarction, severe cardiac failure, transient ischemic attack or acute ischemic stroke and other ischemic events in the past 3 months; (5) allergy to RJQM; (6) the presence of severe hepatic or renal insufficiency, malignant tumors, mental anomalies, pregnancy, or preparation for pregnancy prior to randomization, and other patients considered by the investigator as unsuitable for participation in this study; and (7) those who have been involved in a clinical trial of other drugs in the past 6 months.
Investigators
Similar Trials
Not yet recruiting
Phase 1
Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenzainfluenzaITMCTR2000002885onghua Hospital Shanghai University of Traditional Chinese Medicine
Not yet recruiting
Phase 1
A randomized controlled trial of Ruanjian Qingmai Granule in the treatment of peripheral arterial diseaseperipheral arterial diseaseITMCTR2200005580shanghai TCM-Integrated Hospital
Recruiting
Not Applicable
Evaluation of the clinical efficacy of Qinghuatanshi Decoction in the treatment of Plasma cell mastitis during perioperative periodPlasma cell mastitisITMCTR2100005055Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Completed
Not Applicable
Evaluation of efficacy and safety of the Qing Dai in patients with ulcerative colitis: A muticenter, double-blind, randomized controlled trial.ulcerative colitisJPRN-UMIN000019103The Jikei University Kashiwa Hospital68
Not yet recruiting
Phase 4
Evaluation of the clinical efficacy of Guanxinning tablets in the treatment of patients with carotid atherosclerotic plaqueCarotid atherosclerotic plaque formationITMCTR2100005440Dongzhimen Hospital, Beijing University of Chinese Medicine